Display options
Cite
Su J, Xu HT, Yu JJ, et al. Luteolin Ameliorates Hypertensive Vascular Remodeling through Inhibiting the Proliferation and Migration of Vascular Smooth Muscle Cells. Evid Based Complement Alternat Med. 2015;2015:364876doi: 10.1155/2015/364876.
Su, J., Xu, H. T., Yu, J. J., Gao, J. L., Lei, J., Yin, Q. S., Li, B., Pang, M. X., Su, M. X., Mi, W. J., Chen, S. H., & Lv, G. Y. (2015). Luteolin Ameliorates Hypertensive Vascular Remodeling through Inhibiting the Proliferation and Migration of Vascular Smooth Muscle Cells. Evidence-based complementary and alternative medicine : eCAM, 2015364876. https://doi.org/10.1155/2015/364876
Su, Jie, et al. "Luteolin Ameliorates Hypertensive Vascular Remodeling through Inhibiting the Proliferation and Migration of Vascular Smooth Muscle Cells." Evidence-based complementary and alternative medicine : eCAM vol. 2015 (2015): 364876. doi: https://doi.org/10.1155/2015/364876
Su J, Xu HT, Yu JJ, Gao JL, Lei J, Yin QS, Li B, Pang MX, Su MX, Mi WJ, Chen SH, Lv GY. Luteolin Ameliorates Hypertensive Vascular Remodeling through Inhibiting the Proliferation and Migration of Vascular Smooth Muscle Cells. Evid Based Complement Alternat Med. 2015;2015:364876. doi: 10.1155/2015/364876. Epub 2015 Sep 30. PMID: 26495010; PMCID: PMC4606148.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2015;2015:364876. doi: 10.1155/2015/364876. Epub 2015 Sep 30.

Luteolin Ameliorates Hypertensive Vascular Remodeling through Inhibiting the Proliferation and Migration of Vascular Smooth Muscle Cells.

Evidence-based complementary and alternative medicine : eCAM

Jie Su, Han-Ting Xu, Jing-Jing Yu, Jian-Li Gao, Jing Lei, Qiao-Shan Yin, Bo Li, Min-Xia Pang, Min-Xia Su, Wen-Jia Mi, Su-Hong Chen, Gui-Yuan Lv

Affiliations

  1. Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
  2. Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
  3. Zhejiang University of Technology, Hangzhou, Zhejiang 310014, China.
  4. Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China ; Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.

PMID: 26495010 PMCID: PMC4606148 DOI: 10.1155/2015/364876

Abstract

Objectives. Preliminary researches showed that luteolin was used to treat hypertension. However, it is still unclear whether luteolin has effect on the hypertensive complication such as vascular remodeling. The present study was designed to investigate the effect of luteolin on the hypertensive vascular remodeling and its molecular mechanism. Method and Results. We evaluated the effect of luteolin on aorta thickening of hypertension in spontaneous hypertensive rats (SHRs) and found that luteolin could significantly decrease the blood pressure and media thickness of aorta in vivo. Luteolin could inhibit angiotensin II- (Ang II-) induced proliferation and migration of vascular smooth muscle cells (VSMCs). Dichlorofluorescein diacetate (DCFH-DA) staining result showed that luteolin reduced Ang II-stimulated ROS production in VSMCs. Furthermore, western blot and gelatin zymography results showed that luteolin treatment leaded to a decrease in ERK1/2, p-ERK1/2, p-p38, MMP2, and proliferating cell nuclear antigen (PCNA) protein level. Conclusion. These data support that luteolin can ameliorate hypertensive vascular remodeling by inhibiting the proliferation and migration of Ang II-induced VSMCs. Its mechanism is mediated by the regulation of MAPK signaling pathway and the production of ROS.

References

  1. Hypertension. 1996 Nov;28(5):785-90 - PubMed
  2. Nephrol Dial Transplant. 2010 Feb;25(2):364-72 - PubMed
  3. Circ Res. 2002 Feb 22;90(3):251-62 - PubMed
  4. Physiol Rev. 2001 Jul;81(3):999-1030 - PubMed
  5. Toxicol Appl Pharmacol. 2013 Sep 1;271(2):184-95 - PubMed
  6. J Hypertens Suppl. 1990 Dec;8(7):S225-32 - PubMed
  7. Arch Pharm Res. 2006 Jan;29(1):67-72 - PubMed
  8. J Ethnopharmacol. 2013 Nov 25;150(2):507-13 - PubMed
  9. Endocrinology. 2000 Sep;141(9):3120-6 - PubMed
  10. Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1257-62 - PubMed
  11. Oncol Res. 2009;17(11-12):519-26 - PubMed
  12. Hypertension. 1997 Jan;29(1 Pt 2):334-9 - PubMed
  13. Inflammation. 2011 Dec;34(6):620-9 - PubMed
  14. Circ Res. 2003 May 2;92(8):827-39 - PubMed
  15. FEBS J. 2012 May;279(10):1834-43 - PubMed
  16. Planta Med. 2010 Mar;76(5):433-8 - PubMed
  17. Biochem Pharmacol. 2005 Jun 15;69(12 ):1715-21 - PubMed
  18. Curr Cancer Drug Targets. 2008 Nov;8(7):634-46 - PubMed
  19. Mini Rev Med Chem. 2009 Jan;9(1):31-59 - PubMed
  20. Clin Invest Med. 1993 Jun;16(3):177-86 - PubMed
  21. Chest. 2000 Mar;117(3):841-54 - PubMed
  22. Cell Signal. 2003 May;15(5):455-62 - PubMed
  23. J Cardiovasc Pharmacol. 2008 Jun;51(6):523-31 - PubMed
  24. Pharmacol Res. 2010 Apr;61(4):281-7 - PubMed
  25. Arthritis Rheum. 1999 Nov;42(11):2491 - PubMed
  26. Curr Hypertens Rep. 2009 Jun;11(3):182-9 - PubMed
  27. Gut. 1994 Apr;35(4):530-5 - PubMed
  28. FASEB J. 2001 Apr;15(6):1098-100 - PubMed
  29. Cardiovasc Res. 2008 May 1;78(2):274-85 - PubMed
  30. Biochem Biophys Res Commun. 2008 Oct 10;375(1):151-5 - PubMed
  31. J Pharmacol Sci. 2010;113(2):161-8 - PubMed
  32. PLoS One. 2012;7(2):e31850 - PubMed
  33. Hypertension. 2007 Aug;50(2):299-305 - PubMed
  34. Clin Exp Pharmacol Physiol. 2002 Jul;29(7):537-43 - PubMed
  35. Physiol Rev. 1982 Apr;62(2):347-504 - PubMed
  36. J Agric Food Chem. 2009 Apr 22;57(8):3087-93 - PubMed
  37. Med Biol Eng Comput. 2008 May;46(5):461-7 - PubMed
  38. Eur J Nutr. 2014 Feb;53(1):269-75 - PubMed
  39. Am J Physiol Cell Physiol. 2007 Jan;292(1):C82-97 - PubMed
  40. Circ Res. 1994 Jun;74(6):1141-8 - PubMed
  41. Hypertension. 2011 Feb;57(2):245-54 - PubMed
  42. Biosci Biotechnol Biochem. 2006 Mar;70(3):718-21 - PubMed
  43. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2482-7 - PubMed
  44. Nature. 1993 Apr 29;362(6423):801-9 - PubMed
  45. J Ocul Pharmacol Ther. 2004 Jun;20(3):189-200 - PubMed
  46. Phytother Res. 2013 Nov;27(11):1678-84 - PubMed
  47. Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H435-46 - PubMed
  48. Can J Cardiol. 2010 Mar;26 Suppl A:17A-21A - PubMed
  49. Evid Based Complement Alternat Med. 2013;2013:265061 - PubMed
  50. J Clin Invest. 2005 Sep;115(9):2508-16 - PubMed

Publication Types